Sirolimus-eluting stent fractures leading to restenosis in cardiac allograft vasculopathy

Cardiovasc Revasc Med. 2010 Apr-Jun;11(2):120-3. doi: 10.1016/j.carrev.2009.08.001.

Abstract

Cardiac allograft vasculopathy (CAV) is the most common cause of long-term graft failure after heart transplantation. In the absence of a specific treatment for this condition, percutaneous coronary revascularization (PCI) has been the main palliative treatment. Although long-term results are unknown, use of drug-eluting stents (DES) has been shown to have favorable outcome when used in heart transplant patients for treatment of focal lesions in CAV. We report the case of a 77-year-old male who presented with restenosis secondary to DES stent fracture (SF) after treatment of CAV with sirolimus-eluting stents (SES).

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Angioplasty, Balloon, Coronary / adverse effects*
  • Angioplasty, Balloon, Coronary / instrumentation*
  • Cardiovascular Agents / administration & dosage*
  • Coronary Angiography
  • Coronary Restenosis / diagnostic imaging
  • Coronary Restenosis / etiology*
  • Coronary Restenosis / therapy
  • Coronary Stenosis / diagnostic imaging
  • Coronary Stenosis / etiology
  • Coronary Stenosis / therapy*
  • Drug-Eluting Stents*
  • Heart Transplantation / adverse effects*
  • Humans
  • Male
  • Prosthesis Design
  • Prosthesis Failure
  • Sirolimus / administration & dosage*
  • Transplantation, Homologous
  • Ultrasonography, Interventional

Substances

  • Cardiovascular Agents
  • Sirolimus